Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPExtreme in Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
NCT02268695Phase 2Completed
- Sponsor
- GORTEC
- Start
- Oct 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of docetaxel in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Overall Survival. Started Oct 2014; status: completed.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02268695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268695.